Compare · GILD vs SOPH
GILD vs SOPH
Side-by-side comparison of Gilead Sciences Inc. (GILD) and SOPHiA GENETICS SA (SOPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and SOPH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.26B, about 413.5x SOPH ($375.5M).
- Over the past year, GILD is up 16.7% and SOPH is up 64.1% - SOPH leads by 47.4 points.
- SOPH has been more active in the news (23 items in the past 4 weeks vs 17 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 13 for SOPH).
- Company
- Gilead Sciences Inc.
- SOPHiA GENETICS SA
- Price
- $125.05+0.17%
- $5.25-2.42%
- Market cap
- $155.26B
- $375.5M
- 1M return
- -4.14%
- +4.17%
- 1Y return
- +16.66%
- +64.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2021
- News (4w)
- 17
- 23
- Recent ratings
- 25
- 13
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
SOPHiA GENETICS SA
Sophia Genetics SA, a cloud-based software-as-a-service platform that enables healthcare institutions to get insights from their data. The company offers SOPHiA DDM for solid tumors. Sophia Genetics SA was founded in 2012 and is based in Saint-Sulpice, Switzerland.
Latest GILD
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
Latest SOPH
- Chief Financial Officer Cardoza George sold $4,164 worth of Ordinary Shares (774 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.25% to 310,684 units (SEC Form 4) to satisfy withholding obligation
- President Muken Ross sold $2,270 worth of Ordinary Shares (422 units at $5.38) as part of a pre-agreed trading plan, decreasing direct ownership by 0.06% to 680,489 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by SOPHiA GENETICS SA
- Director Cox Troy was granted 19,724 units of Ordinary Shares, increasing direct ownership by 6% to 328,743 units (SEC Form 4)
- Director Ossipow Vincent was granted 19,724 units of Ordinary Shares, increasing direct ownership by 4% to 522,860 units (SEC Form 4)
- Director Hibbs Kathy L was granted 19,724 units of Ordinary Shares, increasing direct ownership by 22% to 109,492 units (SEC Form 4)
- Director Hirsch Didier was granted 19,724 units of Ordinary Shares, increasing direct ownership by 9% to 240,220 units (SEC Form 4)
- Director Cossery Jean-Michel was granted 19,724 units of Ordinary Shares, increasing direct ownership by 11% to 206,212 units (SEC Form 4)
- SEC Form 6-K filed by SOPHiA GENETICS SA
- SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting